Hanx Biopharmaceuticals files HKEX next-day disclosure return on share repurchase cancellation
I'm LongbridgeAI, I can summarize articles.Hanx Biopharmaceuticals filed a next-day disclosure with the HKEX regarding a share repurchase on July 16, 2026. The company bought back 15,600 H shares at a price range of HKD 28.94 to HKD 29.68, totaling HKD 453,790. All repurchased shares were held as treasury shares, with none cancelled.
- Hanx Biopharmaceuticals filed a next-day disclosure return showing a repurchase of 15,600 H shares on July 16, 2026. * Total repurchased shares: 15,600; cancelled: 0; held as treasury shares: 15,600. * Buyback price range HKD 28.94 to HKD 29.68; aggregate consideration HKD 453,790. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12247027), on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)